Richard Eek
Albury, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
The Utility of Molecular Tumor Profiling for Patients With Advanced or Rare Cancer in a Regional Australian Setting.
Journal: Asia-Pacific journal of clinical oncology
Published: November 13, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Journal: Haematologica
Published: September 19, 2023
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 15, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Journal: Haematologica
Published: December 05, 2022
SARS-CoV-2 Seroprevalence in a Cohort of International Travellers Returning to Rural Australia: Enablers and Barriers to Containment of COVID-19.
Journal: Australian and New Zealand journal of public health
Published: March 23, 2022
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Journal: Lancet (London, England)
Published: November 06, 2017
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2016
Last Updated: 09/26/2026